Compare Freshworks Inc (FRSH) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Tango Therapeutics Inc. — how do they compare? Freshworks Inc trades at $13.72 (market cap $3.57B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Freshworks Inc and Tango Therapeutics Inc. are close in size by market cap, and Freshworks Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 40 Days and Tango Therapeutics Inc. for 0 Days on average.
| FRSH | TNGX | |
|---|---|---|
Market Cap | $3.57B | $3.74B |
Volume | 4,701,335 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $13.92 | $32.90 |
52-Week Low | $6.88 | $7.50 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $2.94B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.90, down 0.14% with a bullish technical outlook. The company achieved its first GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains strong at 16% YoY, with improving margins and positive cash flow trends. Analyst consensus is evenly split between Buy and Hold ratings with a $14.60 price target.
FRSH presents a compelling growth story with accelerating profitability and AI-driven product expansion. Key risks include competitive pressures in the SaaS sector and execution challenges in enterprise market penetration. The stock's current valuation at 22x P/E appears reasonable given the company's growth trajectory and improving financial metrics.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
